Connect Biopharma Holdings Limited - Ordinary Shares (NQ:CNTB)

1.170 -0.560 (-32.37%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 15, 2026 Add to My Watchlist

Price and Volume

Volume	11,550,631
Open	1.270
Bid (Size)	1.120 (200)
Ask (Size)	1.150 (1,200)
Prev. Close	1.730
Today's Range	1.061 - 1.300
52wk Range	1.230 - 3.820
Shares Outstanding	55,041,247
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

Today 15:00 EDT

Via Chartmill

Keep an eye on the top gainers and losers in Tuesday's session. ↗

Today 12:30 EDT

Via Chartmill

Performance

YTD	-53.6%	-53.6%
1 Month	-53.0%	-53.0%
3 Month	-43.2%	-43.2%
6 Month	-56.7%	-56.7%
1 Year	-26.9%	-26.9%

More News

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

Today 10:30 EDT

Via Chartmill

What's going on in today's pre-market session ↗

Today 8:30 EDT

Via Chartmill

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation

Today 7:00 EDT

From Connect Biopharma Holdings Limited

Via GlobeNewswire

These stocks are moving in today's after hours session ↗

September 03, 2026

Via Chartmill

Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 03, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update

August 12, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

June 17, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Touts Rademikibart’s Edge as SEABREEZE Data Looms in 2026 ↗

May 22, 2026

Via MarketBeat

Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

May 12, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

April 23, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms

April 07, 2026

Via ACCESS Newswire

Wondering what's happening in today's after-hours session? ↗

April 01, 2026

Via Chartmill

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

March 31, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Announces $20.2 Million Private Placement Financing

March 30, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

March 30, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD

March 30, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting

March 10, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference

March 03, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 19, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026

January 12, 2026

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference

November 24, 2025

From Connect Biopharma Holdings Limited

Via GlobeNewswire

Which stocks have an unusual volume on Friday? ↗

November 21, 2025

Via Chartmill

Frequently Asked Questions

Is Connect Biopharma Holdings Limited - Ordinary Shares publicly traded?

Yes, Connect Biopharma Holdings Limited - Ordinary Shares is publicly traded.

What exchange does Connect Biopharma Holdings Limited - Ordinary Shares trade on?

Connect Biopharma Holdings Limited - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Connect Biopharma Holdings Limited - Ordinary Shares?

The ticker symbol for Connect Biopharma Holdings Limited - Ordinary Shares is CNTB on the Nasdaq Stock Market

What is the current price of Connect Biopharma Holdings Limited - Ordinary Shares?

The current price of Connect Biopharma Holdings Limited - Ordinary Shares is 1.170

When was Connect Biopharma Holdings Limited - Ordinary Shares last traded?

The last trade of Connect Biopharma Holdings Limited - Ordinary Shares was at 09/15/26 04:00 PM ET

What is the market capitalization of Connect Biopharma Holdings Limited - Ordinary Shares?

The market capitalization of Connect Biopharma Holdings Limited - Ordinary Shares is 64.40M

How many shares of Connect Biopharma Holdings Limited - Ordinary Shares are outstanding?

Connect Biopharma Holdings Limited - Ordinary Shares has 64M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.